Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]

16195 reported adverse events

Drugs of this class: ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 7270
1 RENAL INJURY 4294
2 CHRONIC KIDNEY DISEASE 4186
3 SKELETAL INJURY 3848
4 TOOTH LOSS 3790
5 BONE LOSS 3658
6 OSTEONECROSIS 3595
7 RENAL FAILURE 3404
8 MULTIPLE FRACTURES 3303
9 PAIN 2923
See all common reactions for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOOTH INJURY 1990 0.4579
1 SKELETAL INJURY 3848 0.3717
2 BONE DEMINERALISATION 281 0.2653
3 BONE LOSS 3658 0.2431
4 BONE DENSITY DECREASED 7270 0.2318
5 MULTIPLE FRACTURES 3303 0.2009
6 TOOTH LOSS 3790 0.1826
7 RENAL INJURY 4294 0.1444
8 BONE DENSITY ABNORMAL 451 0.1206
9 OSTEOPENIA 1821 0.1199
See all enriched reactions for Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]